Etiology of dyspepsia: Implications for empirical therapy

Canadian Journal of Gastroenterology

Volumn 16, Issue 9, 2002, Pages 635-641

  Hunt, Richard H ^a   Fallone, Carlo ^a   van Zanten, Sander Veldhuyzen ^a   Sherman, Phil ^a   Flook, Nigel ^a   Smaill, Fiona ^a   Thomson, Alan B R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Dyspepsia; Empirical therapy; Functional dyspepsia; Uninvestigated dyspepsia

Indexed keywords

ANTIBIOTIC AGENT; ANXIOLYTIC AGENT; CISAPRIDE; CYCLOOXYGENASE 2 INHIBITOR; KAPPA OPIATE RECEPTOR AGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; SEROTONIN 3 ANTAGONIST; SUBSTANCE P ANTAGONIST;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPEPSIA; EMPIRICISM; EPIGASTRIC PAIN; ESOPHAGITIS; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; NAUSEA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; SATIETY; SYMPTOMATOLOGY; UPPER GASTROINTESTINAL TRACT;

EID: 0036753992     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/679683     Document Type: Article

References (42)

1. Thomson A, Armstrong D, Barkun A, et al. Is prompt endoscopy necessary in uninvestigated dyspeptics? Prevalence of upper gastrointestinal abnormalities: the CADET-PE Study. Gastroenterology 2001;120:A50. (Abst)
2. Locke GR III. The epidemiology of functional gastrointestinal disorders in North America. Gastroenterol Clin North Am 1996;25:1-19.
3. Talley N, Zinsmeister A, Scheck C. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259-68.
4. Jones RH, Lipleard S. Prevalence of symptoms of dyspepsia in the community. Br Med J 1989;298:30-2.
5. Tougas G, Chen Y, Hwang P, Liu MM, Eggelston A. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Am J Gastroenterol 1999;94:2845-54.
6. Lydeard S, Jones R. Factors affecting the decision to consult with dyspepsia: comparison of consulters and non-consulters. J R Coll Gen Pract 1989;39:495-8.
7. Talley N. Non-ulcer dyspepsia: current approaches to diagnosis. Am Fam Physician 1993;47:6-10.
8. Danish Dyspepsia Study Group. Value of the unaided clinical diagnosis in dyspeptic patients in primary care. Am J Gastroenterol 2001;96:1417-21.
9. Talley NJ, Colin-Jones D, Koch KL, et al. Functional dyspepsia. A classification with guidelines for diagnosis and management. Gastroenterol Int 1991;4:145-60.
10. Talley NJ, Stanghellini, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999;45:1137-42.
11. Van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. CMAJ 2000;162(Suppl 12):S3-23.
12. Collins SM. Stress and the gastrointestinal tract IV. Modulation of intestinal inflammation by stress: basic mechanisms and clinical relevance. Am J Physiol Gastrointest Liver Physiol 2001;280:G315-8.
13. Bercik P, Collins SM. Current concepts of dyspepsia: the role of the nervous system. In: Hunt RH, Tytgat GNJ, eds. H. pyloyi; Basic Mechanisms to Clinical Cure. Lancaster: Kluwer, 2000:411.
14. Moran TH, Ameglio PJ, Schwartz GJ, McHugh PR. Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK. Am J Physiol 1992;262:R46-50.
15. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet. 1996;347:150-3.
16. Collins SM, McHugh K, Jacobson K, et al. Previous inflammation alters the response of the rat colon to stress. Gastroenterology 1996;111:1509-15.
17. Schmulson MJ, Mayer EA. Gastrointestinal sensory abnormalities in functional dyspepsia. Baillieres Clin Gastroenterol 1998;12:545-56.
18. Pelicic V, Reyrat JM, Sartori L, et al. Helicobacter pylori VacA cytotoxin associated with the bacteria increases epithelial permeability independently of its vacuolating activity. Microbiology 1999;145:2043-50.
19. Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated intracellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 1996;111:1200-5.
20. Dickhaus B, Firooz N, Stains J, et al. Psychological stress increases visceral sensitivity in patients with IBS but not controls. Gastroenterology 2001;120:A67. (Abst)
21. Gregory LJ, Yaguez L, Altmann C, et al. Identifying the neural network for selective attention to visceral sensation using functional magnetic resonance imaging. Gastroenterology 2001;120:A23. (Abst)
22. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530-6.
23. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
24. Hamilton JW, Boisen Rj, Yuamamoto DT, Wagner JL, Reicheldefer M. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci 1998;33:518-22.
25. Johnson LF, DeMeester TR. Evaluation of elevation of the head of the bed, bethanechol and antacid foam tablets on gastroesophageal reflux. Dig Dis Sci 1981;26:673-80.
26. Talley N, Silverstein M, Agreus L, et al. AGA technical review: evaluation of dyspepsia. Gastroenterology 1998;114:582.
27. Chiba N, Veldhuyzen van Zanten SJO, Sinclair P, Ferguson RA, Escoledo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-positive Helicobacter pylori (CADET-Hp) randomised controlled trial. Br Med J 2002;324:1012-6.
28. Lahaie RG, Lahaie M-A, Boivin M, et al. Changing prevalence of H. pylori infection in endoscopically demonstrated duodenal ulcer. Gastroenterology 2000;118:A766. (Abst)
29. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;134:361-9.
30. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ 2000;321:659-64.
31. Blaser MJ. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999;179:1523-30.
32. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:748-89.
33. Hunt RH, Fallone CA, Thomson ABR. Canadian Helicobacter pylori consensus conference update: infections in adults. Can J Gastroenterol 1999; 13:213-7.
34. Meinechi-Schmidt V. Predominant symptoms (Rome II) are no better than symptom clusters (Rome I) for the prediction of PPI response in patients with acid related symptoms from general practice. Gastroenterology 2001;120(Suppl):A51. (Abst)
35. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastro-esophageal reflux disease. Am J Gastroenterol 1997;92:1997-2000.
36. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomized trial. Lancet 2000;356:455-20.
37. 2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994;343:811-6.
38. Gold BD, Collectti RB, Abbott M, et al. Medical Position Statement: The North American Society for Pediatric Gastroenterology and Nutrition. Helicobacter pylori Infection in Children: Recommendations for Diagnosis and Treatment. J Pediatr Gastroenterol Nutr 2000;31:490-7.
39. Sherman P, Hassall E, Hunt RH, et al. Canadian Helicobacter Study Group Consensus Conference on the Approach to Helicobacter pylori Infection in Children and Adolescents. Can J Gastroenterol 1999;13:533-59.
40. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
41. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic GERD Study Group. Gastroenterology. 1999;117:319-26.
42. Lazzaroni M, Bianchi Porro G. Nonsteroidal anti-inflammatory drug gastropathy and Helicobacter pylori: the search for an improbable consensus. Am J Med 2001;110:50S-4S.